| Title | Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. |
| Publication Type | Journal Article |
| Year of Publication | 2022 |
| Authors | Sartor O, George D, Tombal B, Agarwal N, Higano CS, Sternberg CN, Miller K, Jiao XL, Guo H, Sandström P, Bruno A, Verholen F, Saad F, Shore N |
| Journal | Future Oncol |
| Volume | 18 |
| Issue | 1 |
| Pagination | 35-45 |
| Date Published | 2022 Jan |
| ISSN | 1744-8301 |
| Keywords | Abiraterone Acetate, Aged, Aged, 80 and over, Benzamides, Bone Neoplasms, Humans, Male, Middle Aged, Nitriles, Phenylthiohydantoin, Prednisone, Prostatic Neoplasms, Castration-Resistant, Radium, Retrospective Studies |
| Abstract | To evaluate real-world clinical outcomes of radium-223 or alternative novel hormonal therapy (NHT) following first-line NHT for metastatic castration-resistant prostate cancer (mCRPC). Retrospective analysis of the US Flatiron database (ClinicalTrials.gov identifier: NCT03896984). In the radium-223 cohort (n = 120) versus the alternative NHT cohort (n = 226), proportionally more patients had prior symptomatic skeletal events and bone-only metastases, and first-line NHT duration was shorter. Following second-line therapy, 49 versus 39% of patients received subsequent life-prolonging therapy; of these, 47 versus 76% received taxane. Median overall survival was 10.8 versus 11.2 months. Real-world patients with mCRPC had similar median overall survival following second-line radium-223 or alternative NHT after first-line NHT. Many patients received subsequent therapy, with less taxane use after radium-223. |
| DOI | 10.2217/fon-2021-0886 |
| Alternate Journal | Future Oncol |
| PubMed ID | 34636627 |
| Grant List | / / Bayer HealthCare / |